Do you prefer using an anthracycline or non-anthracycline adjuvant regimen in BRCA+ premenopausal patients with localized HR+ breast cancer?

My choice of chemotherapy for localized BRCA+ breast cancer is guided by the patient's risk factors such as tumor grade, tumor size, presence or absence of lymphovascular invasion, number of lymph nodes involved, Oncotype dx result, and the patient's age. For small, node negative, HR+, HER2- breast ...